HMHuawei Mao

Huawei Mao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huawei Mao has a total of 134 co-authors. Here are the top co-authors by number of shared publications:

  • Tongxin Han

    Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    11 shared publications
  • Yan Li

    Department of Rheumatology, Ministry of Education Key Laboratory of Major Diseases in Children, Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    11 shared publications
  • Mengyue Deng

    Department of Rheumatology and Immunology, Beijing Children’s Hospital of Capital Medical University, National Center for Children’s Health of China

    9 shared publications
  • Zhou Shu

    Department of Rheumatology and Immunology, Beijing Children’s Hospital of Capital Medical University, National Center for Children’s Health of China

    7 shared publications
  • Wenxiu Mo

    Department of Rheumatology, Ministry of Education Key Laboratory of Major Diseases in Children, Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    6 shared publications
  • Fei Sun

    Department of Immunology, Ministry of Education Key Laboratory of Major Diseases in Children Beijing Key Laboratory of Precision Diagnosis and Treatment of Pediatric Immune Diseases, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health

    5 shared publications

Latest Publications

  • Open Access

    Atomoxetine-associated Raynaud’s phenomenon in children: an under-recognized risk of non-stimulant ADHD therapy

    by Wenxiu Mo, Lin Liu, Zheyu Cui, Yan Li, Huawei Mao

    Raynaud’s phenomenon (RP) is an increasingly recognized yet still underreported adverse effect of ADHD pharmacotherapy. Whereas stimulant-associated RP is well documented, atomoxetine-related RP has surfaced only in isolated pediatric cases, leaving a gap in our understanding of non-stimulant toxicity. This narrative review reports the first Asian pediatric case identified in English- and regional-language literature and synthesizes the global evidence base, integrating five pediatric cases, targeted literature retrieval, and disproportionality analyses of FAERS and WHO VigiBase. Atomoxetine carries a consistent pharmacovigilance signal for RP. Beyond the elevation of synaptic cleft norepinephrine, the five cases point to suspected contributors: plasma drug concentration, CYP2D6-mediated metabolic variability—particularly relevant in East Asian populations—and individual susceptibility with superimposed triggers. Onset latency is highly variable (hours to years), and the course in reported cases is milder and fully reversible, without digital ulceration, features consistent with, though not determined by, the sustained, gradual peripheral noradrenergic elevation produced by selective norepinephrine transporter inhibition, in contrast to the rapid catecholamine surges typical of stimulants. These findings call for longitudinal vigilance beyond the titration phase, prompt exclusion of secondary causes, and systematic pharmacovigilance reporting.

  • Open Access

    A novel stop-loss variant in ISG15 causes C-terminal dysfunction and impairs USP18-mediated negative feedback

    by Wanyu Zhang, Xiongbin Chen, Yulu Li, Xingfeng Yao, Jinyan Huang, Yijiu Gao, Wenlu Xing, Dan Lu, Mengyue Deng, Zhou Shu, et al.

    Introduction: ISG15 is a type I interferon (IFN-I)-inducible ubiquitin-like protein that restrains IFN-I signaling. Classical ISG15 deficiency is thought to cause disease mainly by disrupting USP18 stabilization, which leads to sustained IFN-I signaling and interferon-driven autoinflammation. Whether patient-derived C-terminal ISG15 variants can impair IFN-I negative feedback through altered C-terminal functional presentation has remained unclear. Methods: We studied a Chinese boy with early-onset recurrent fever, severe ulcerative skin lesions, and elevated liver enzymes. Whole-exome sequencing was performed to identify ISG15 variants. Patient peripheral blood mononuclear cells (PBMCs) and skin tissue were analyzed for IFN-I pathway activation. Functional effects of the identified variants were assessed in 293T cells, and structural analysis was performed. The patient was treated with the JAK inhibitor baricitinib. Results: Two novel compound heterozygous ISG15 variants were identified: c.234C>A, which produced a truncated ISG15 protein, and c.498A>T, a stop-loss variant predicted to extend the ISG15 C-terminus and associated with markedly impaired ISGylation. Patient PBMCs and skin tissue showed increased p-STAT1 signaling and IFN-I pathway activation, with decreased USP18 expression and altered ISG15-USP18 regulation in PBMCs. In 293T cells, c.498A>T alone did not reduce USP18 abundance, suggesting that this variant contributes to disease through impaired C-terminal functional presentation rather than USP18 loss alone. Structural analysis suggested that the C-terminal extension may alter LRLRGG motif presentation, weakening ISG15-USP18-mediated negative feedback. Baricitinib reduced IFN-I-related markers and was associated with improvement of ulcerative skin lesions and liver enzyme abnormalities. Discussion: This study expands the genetic and mechanistic spectrum of ISG15-associated type I interferonopathy, and supports that JAK-STAT inhibition with baricitinib can effectively control IFN-I-driven inflammation.

  • Open Access

    Editorial: Community series in unraveling the molecular mechanisms of cytokine signaling in regulating inflammatory diseases, volume II

    by Jian Zheng, Huawei Mao, Wai Po Chong

    Chronic inflammation, driven by dysregulated cytokine networks, lies at the heart of a vast spectrum of debilitating conditions, from autoimmune disorders like rheumatoid arthritis (RA) and lupus nephritis (LN) to complications like post-surgical fibrosis and recurrent spontaneous abortion (RSA). Despite their prevalence and impact, the intricate molecular choreography cytokine signaling in these diseases remains incompletely mapped. This second volume of our Special Issue, "Unraveling the Molecular Mechanisms of Cytokine Signaling in Regulating Inflammatory Diseases," directly confronts this knowledge gap. The compelling research presented herein provides critical mechanistic insights into cytokine pathways, revealing novel regulatory nodes, unexpected cellular dialogues, and promising therapeutic targets, collectively advancing our journey towards precision immunology.The core mission of this issue -to dissect the molecular mechanisms of cytokine signaling dysregulation and identify pathways for therapeutic intervention -is vividly reflected in the diverse studies published. A central theme is the development of sophisticated strategies to restore immune balance. Qiao et al. exemplify this by demonstrating the remarkable long-term ehicacy of combining an αCD4 antibody with a specific retinal antigen (IRBP1-20) in a chronic model of autoimmune uveitis. Their work transcends acute suppression, showing sustained long-term disease control, mediated by induced regulatory T cells (Tregs) and profound downregulation of ocular inflammatory cytokine gene networks. This study underscores the power of targeted immunomodulation to reprogram the local inflammatory microenvironment for durable benefit.Understanding the specific molecular pathways hijacked in inflammation is paramount for targeted therapy. Wang et al. delve into the complex world of fibrosis, a common and often treatment-refractory outcome of dysregulated healing. They identify Interferon Induced Transmembrane Protein 1 (IFITM1) as a critical regulator of epidural scar hyperplasia post-laminectomy. Their meticulous work unveils a dual mechanism: IFITM1 promotes fibroblast proliferation and activation via the SMAD3 pathway while simultaneously driving adipocyte-to-fibroblast transformation by suppressing the fatty acid synthesis protein CBR4. This intricate crosstalk between IFITM1, SMAD3, and metabolic reprogramming in adipocytes highlights novel targets (IFITM1, CBR4) for preventing pathological fibrosis.The dialogue between immune cells and tissue-resident cells is another crucial layer of cytokine regulation explored in this issue. Yan et al. shed light on the tragic pathophysiology of RSA by elucidating a devastating positive feedback loop between M1 macrophages (M1-Mφ) and trophoblasts. They identify CXCL9, elevated in RSA decidua, as the key mediator released by M1-Mφ. CXCL9 signals through CXCR3 on trophoblasts, activating JAK/STAT1 and subsequently inducing the transcription factor ZEB1 via IRF1. ZEB1 then drives CCL2 production, recruiting more macrophages and perpetuating inflammation while directly inhibiting trophoblast migration and invasion -essential processes for successful pregnancy. This CXCL9/STAT1/IRF1/ZEB1/CCL2 axis represents a self-amplifying inflammatory circuit and a compelling target for breaking the cycle of RSA.The integration of metabolism and immune function is increasingly recognized as fundamental. Zhang et al. provide a comprehensive systems-level analysis in RA, integrating transcriptomics and clinical data. They pinpoint dysregulation in amino acid, energy, and TCA cycle pathways as key discriminators of RA. Crucially, they construct a co-expression network linking the TCA cycle to immune infiltration and identify 11 hub genes (including COX7C, validated in vivo) that act as molecular bridges between metabolic reprogramming and immune dysregulation. Their LASSO diagnostic model, based on these genes, ohers not only diagnostic potential but also a framework for understanding how metabolic shifts fuel synovitis, paving the way for metabolically targeted interventions.Exploring specific cytokine-mediated regulatory mechanisms, Giraulo et al. investigate the purinergic anti-inflammatory pathway in psoriasis. They demonstrate that the proinflammatory cytokine Oncostatin M (OSM), part of the psoriatic "M5 cocktail," paradoxically upregulates the ecto-enzyme CD73 on keratinocytes via the JAK/MAPK pathway. CD73 generates extracellular adenosine, which then signals primarily through upregulated A2A receptors (A2AR) on both keratinocytes and dermal fibroblasts to suppress IL-8 release. This work reveals a crucial endogenous anti-inflammatory feedback loop (OSM / CD73 / Adenosine / A2AR) within the inflamed skin, suggesting that boosting CD73 activity or A2AR signaling could be therapeutic strategies.Beyond specific diseases, Dong and Yue's systematic review reframes Obstructive Sleep Apnea (OSA) as a potent driver of systemic immune dysregulation. They synthesize evidence showing how intermittent hypoxia and sleep fragmentation activate master regulators like HIF-1α, NF-κB, and the NLRP3 inflammasome across innate and adaptive immune cells. This chronic immune activation underpins the systemic comorbidities of OSA (cardiovascular, metabolic, cognitive). Their work emphasizes that understanding the immunology of OSA is essential for developing therapies that address its systemic consequences, moving beyond mere airway management.Finally, robust clinical validation of cytokine pathways is essential. Zhou et al. present a rigorous meta-analysis confirming Interleukin-18 (IL-18), a key pyroptosis-related cytokine, as a significant biomarker in Lupus Nephritis (LN). They demonstrate significantly elevated circulating IL-18 levels in LN patients compared to SLE patients without nephritis and healthy controls, with levels highest in severe Class IV LN. This provides strong clinical...

  • Open Access

    Effectiveness and safety analysis of initial treatment with belimumab in childhood-onset systemic lupus erythematosus

    by Yan Li, Jing Ma, Mengyue Deng, Qin Ma, Ziwei He, Tongxin Han, Yurong Piao, Fei Sun, Zhou Shu, Wenxiu Mo, et al.

    Objective: A retrospective cohort study to analyze the effectiveness and safety of belimumab using in the initial treatment of childhood-onset systemic lupus erythematosus (cSLE). Methods: We collected clinical data from all children with a first diagnosis of cSLE admitted to our center between 1 April 2021 and 1 November 2024. Patients who initiated belimumab within 1 month of diagnosis were assigned to the belimumab group, and those who did not receive belimumab comprised the control group. Propensity score matching (PSM) was applied to balance baseline characteristics between the groups. The proportion of lupus low disease activity status (LLDAS) and remission (Definitions of Remission in Systemic Lupus Erythematosus, DORIS), the disease activity scores, laboratory tests, glucocorticoid dosage, and adverse effects during the courses of treatment in two groups were analysis. Results: There were 39 cases in both the belimumab group and the control group. The belimumab group exhibited a higher proportion of patients achieving LLDAS (31/39 vs. 14/39, p < 0.001) and DORIS (18/39 vs. 5/39, p =0.002) compared to the control group at 12 months after treatment. Additionally, the time to achieve LLDAS and DORIS was significantly shorter in the belimumab group (log-rank p< 0.001). However, no statistical variances were observed between the two groups in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, physician global assessment (PGA) scores, complement levels, negative rates of anti-double-stranded DNA (anti-dsDNA) antibodies at each follow-up interval. From the 7th to the 12th month of treatment, the daily prednisone dose in the belimumab group was lower than in the control group. After 12 months of treatment with belimumab, B cells (p< 0.001) and immunoglobulin G (IgG) (p< 0.001) showed a significant decrease from baseline. No infusion-related adverse reactions were observed in children receiving belimumab, and the infection rate did not differ significantly from the control group. Conclusions: Adding belimumab to initial therapy facilitates quicker disease control and expedites glucocorticoid tapering in children, which can be a new treatment strategy for cSLE.

  • Open Access

    Clinical, immunological characterisation and treatment response of patients with syndrome of undifferentiated recurrent fever in Chinese children and adolescents: a single-centre cohort study

    by Xiongbin Chen, Wenlu Xing, Yulu Li, Mengyang Yang, Zhou Shu, Huawei Mao

    Background: Syndrome of undifferentiated recurrent fevers (SURF) is a heterogeneous disorder characterised by recurrent fevers and autoinflammation in the absence of a confirmed molecular diagnosis of hereditary recurrent fever (HRF) and periodic fever, adenitis, pharyngitis, aphthous stomatitis (PFAPA) syndrome. The aim of this study is to characterise the clinical and immunological features of SURF patients and to analyse their cytokine signature and treatment patterns. Methods: Between 2022 and 2024, we enrolled 191 patients who presented to Bei Jing Children’s Hospital, Department of Immunology, with the chief complaint of recurrent fever. Fifty-seven patients met the criteria for SURF, 70 met the criteria for PFAPA and 64 met the criteria for FMF. Baseline data and blood samples were collected from patients at enrolment or at routine clinical visits. Clinical and immunological characteristics and cytokine levels were analysed. Results: In SURF patients, gastrointestinal symptoms(abdominal pain and vomiting or diarrhoea) were more prominent than in PFAPA patients. However, the difference in gastrointestinal symptoms between SURF patients and FMF patients was not significant. Pharyngitis and cervical adenitis were both seen in SURF and PFAPA patients while the frequency was higher in PFAPA patients. Family history was significantly higher in FMF patients than in SURF patients. The family history was similar between SURF patients and PFAPA patients. Treatment patterns differ between SURF and PFAPA (or FMF) patients. On-demand steroids were more likely prescribed in PFAPA patients, while colchicine was more commonly prescribed in SURF patients. However, no statistically significant differences were found in the prescription of colchicine between SURF and FMF patients. FMF patients were more commonly prescribed on-demand steroids than SURF patients. But SURF patients were more likely prescribed NSAIDs than FMF patients. The B-cell populations and immunoglobulin (Ig) levels (IgG, IgA, IgM and IgE) were similar in both SURF and PFAPA patients (or FMF patients). The proportion of helper T cells (Th cells) (CD3+CD4+) was significantly lower in SURF patients compared to PFAPA patients. However, the proportion of natural killer cells (NK cells) (CD3-CD56+) was significantly higher in SURF patients compared to PFAPA patients. The proportion of cytotoxic T cells (CD3+CD8+) was significantly higher in FMF patients compared to SURF patients. But the proportion and absolute count of natural killer cells (NK cells) (CD3-CD56+) was significantly lower in FMF patients compared to SURF patients. Cytokine levels between SURF and PFAPA patients (or FMF patients) were similar. SURF patients tended to have higher levels of pro-inflammatory cytokines (including IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α). Both SURF, PFAPA, and FMF patients showed favourable responses to colchicine treatment. Conclusion: This study describes the clinical and immunological characteristics of a large cohort of patients with SURF. This suggests us that SURF is a heterogenous disease. However, the clinical and immunological features and treatment options of SURF patients differ from PFAPA and FMF patients.

  • Open Access

    Clinical Practice of Multidisciplinary Team-Guided Comprehensive Management for Pediatric Patients with Fabry Disease: A Single-Center Case Series

    by Yingchao Liu, Xiaorong Liu, Mei Yang, Quan Wang, Wenmiao Xu, Jiansheng Zeng, Tongxin Han, Huawei Mao, Suyun Qian

    This study aimed to illustrate the practical application and preliminary outcomes of a multidisciplinary team (MDT) approach in managing pediatric Fabry disease (FD), and provide a reference for the clinical management of this rare disease. This single-center, prospective, observational case series was conducted at Beijing Children’s Hospital. Between March 2021 and February 2024, five pediatric patients with FD who were managed by a dedicated MDT were enrolled. The MDT operated under a model of “identification and initiation in outpatient clinics, overall management by the core team, and specialist consultation as needed.” The workflow covered a dual-path diagnostic pathway (MDT-initiated or external referral), pedigree screening, baseline assessment, individualized treatment, and long-term follow-up. Five pediatric FD probands were enrolled, with four diagnosed through the MDT-initiated pathway and one via external referral. For the four newly diagnosed patients, the MDT achieved a definitive diagnosis within 15–30 days of its engagement, despite a prior diagnostic odyssey of 2.0–5.9 years. Pedigree screening identified an asymptomatic sibling, enabling pre-symptomatic diagnosis. All patients commenced enzyme replacement therapy (ERT, agalsidase α) and did not develop adverse events. Through MDT coordination, they currently maintain continuous ERT at medical institutions with a travel time of 20 minutes to 2 hours. MDT-guided pain treatment, primarily with oxcarbazepine, effectively controlled neuropathic pain in most cases and improved quality of life. Psychosocial support alleviated family burdens, achieving treatment cost reimbursement rates of 60%–85%. At one-year follow-up, symptomatic improvement and significant reductions in globotriaosylsphingosine (Lyso-GL-3) levels were observed. The structured MDT approach facilitated accelerated diagnosis, early intervention, and comprehensive care in this pediatric FD cohort, yielding positive short-term outcomes and providing a practical reference for rare disease management.

  • Characterisation and diagnostic model of monogenic lupus

    by Mengyang Yang, Dan Lu, Yulu Li, Xiongbin Chen, Han Yang, Wenxiu Mo, Huawei Mao

    Standardised diagnostic criteria for monogenic lupus are lacking owing to its rarity, diverse phenotypes, and significant heterogeneity in pathogenesis, phenotypic characteristics, disease course, and outcomes. Further, no studies have analysed the characteristics of multiple pathological mechanisms of monogenic lupus. Therefore, we retrospectively summarised the clinical characteristics, genotypes, and treatment of 36 patients with monogenic lupus with 16 different gene mutations admitted to the Department of Immunology at Beijing Children’s Hospital between June 2021 and July 2024. Children with classic lupus were randomly allocated to the control group. A univariate analysis was conducted on different pathogenic pathways to identify relevant significant risk factors. The least absolute shrinkage and selection operator and logistic regression were applied to construct multiple models. The discrimination and calibration abilities of these models were then evaluated, and the optimal diagnostic model for each pathway was proposed. We found that increased vigilance for monogenic lupus is necessary for male children with an onset age of < 8.46 years and a family history. Type-I-interferon disorders should be considered in patients with growth retardation, interstitial lung disease, intracranial calcifications, characteristic rashes, splenomegaly, and elevated liver enzymes. Monogenic lupus involving immune tolerance pathways should be considered in patients with repeated infections, lymphoproliferation, or elevated double-negative T-lymphocyte proportion. Monogenic lupus caused by another pathway should be considered in patients with abdominal symptoms, oral ulcers, and elevated C-reactive protein levels. Overall, our study proposes distinct diagnostic models based on various pathogenic pathways, aiding in early identification and diagnosis of monogenic lupus in children.


  • Open Access

    Mycophenolate Mofetil versus Cyclophosphamide for Initial Therapy in Childhood-Onset Proliferative Lupus Nephritis

    by Ying Wang, Xiaoyan Li, Shan Jian, Jing Li, Junxia Yan, Shuzhen Sun, Zhenle Yang, Weimin Zheng, Qun Li, Qi Zheng, et al.

    Key Points: The total renal response rate in the mycophenolate mofetil group was found to be noninferior to that in the cyclophosphamide group. There was no significant difference in the incidence of adverse drug reactions between the mycophenolate mofetil and cyclophosphamide groups. The reduction in SLE Disease Activity Index scores was similar between the two groups. Background: Recent studies suggest that oral mycophenolate mofetil (MMF) may be similar to intravenous cyclophosphamide in treating lupus nephritis. However, these therapies have not been prospectively compared in childhood-onset lupus nephritis. Methods: In this prospective, multicenter, randomized trial, patients aged 5–17 years with proliferative lupus nephritis (class 3/4±5) and severely increased proteinuria (urine protein-creatinine ratio ≥1000 mg/g and/or 24-hour urinary protein excretion >25 mg/kg) were randomly assigned to receive either MMF or intravenous cyclophosphamide as initial therapy, alongside glucocorticoids. The primary end point was total renal response (TRR) at 24 weeks, with the aim of demonstrating the noninferiority of MMF compared with intravenous cyclophosphamide, using a noninferiority margin of 12%. TRR encompassed complete renal response, primary efficacy renal response, and partial renal response. Secondary end points assessed systemic disease activity and safety. Results: A total of 107 patients were enrolled from 17 hospitals, with 52 assigned to the MMF group (47 completed the 24-week therapy) and 55 assigned to the cyclophosphamide group (48 completed the 24-week therapy). In the intention-to-treat population, the TRR rate was 92% in the MMF group and 89% in the cyclophosphamide group (test for noninferiority, P = 0.008). In the per-protocol population, renal response was observed in 96% of patients in the MMF group versus 94% of patients in the cyclophosphamide group (test for noninferiority, P = 0.009). The difference in TRR rate between the MMF and cyclophosphamide groups was 3% (95% confidence interval, −9% to 15%) in the intention-to-treat population and 2% (95% confidence interval, −9% to 13%) in the per-protocol population. There were no significant differences in the incidence of adverse drug reactions between the MMF and cyclophosphamide groups in the intention-to-treat population (10% versus 15%, continuity correction chi-squared test, P = 0.44). Conclusions: After 24 weeks of therapy, oral MMF was noninferior to intravenous cyclophosphamide as initial therapy for childhood-onset proliferative lupus nephritis and exhibited a similar safety profile. Clinical Trial registry name and registration number: MMF versus cyclophosphamide in the Induction Therapy of Pediatric Active Proliferative lupus nephritis, ClinicalTrials.gov, NCT05495893.


  • Open Access

    Case Report: X-linked agammaglobulinemia with progressive neurodegeneration from immunological to neurological implications

    by Xiaoyi Chen, Hao Gu, Yurong Piao, Yanli Ma, Yiran Zhao, Huawei Mao, Yuan Wang, Jie Deng

    Background: X-linked agammaglobulinemia (XLA) is a rare disorder associated with defective B-lymphocyte differentiation, also known as circulating B-cell deletion or deficiency, reduced levels of all serum immunoglobulin isoforms, and a lack of specific antibody production. XLA has rare neurological complications but has a refractory course and poor prognosis. Here, we report a case of XLA due to a Bruton tyrosine kinase gene variant with progressive neurodegeneration.Case description: We describe a boy with XLA who had recurrent infections since infancy and, after diagnosis was confirmed by genetic testing, was started on regular intravenous immunoglobulin at the age of 5 years. However, after a second episode of suspected meningitis at the age of 4.9 years, he developed motor and cognitive deterioration, becoming unable to sit, walk, eat or speak after 8 months, with frequent tremors and multiple seizures, and died of respiratory failure at the age of 7 years. Magnetic resonance imaging showed progressive whole brain atrophy. Combined with a mild lymphocytic inflammation of the cerebrospinal fluid, we suspected a chronic active infection of the central nervous system, but it was difficult to confirm our suspicion by serological testing due to the inability to produce neutralizing antibodies.Conclusions: Severe progressive neurodegeneration in XLA is rare. With this case we would like to discuss the difficulties in diagnosing infection in patients with XLA and the role of autoimmune mechanisms in the development of neurodegeneration.


  • Paradoxical psoriasis in pediatric tumor necrosis factor-α inhibitor therapy database

    by Yurong Piao, Xiaolin Xu, Xingfeng Yao, Yan Li, Yixin Sun, Tongxin Han, Xiaoling Wang, Huawei Mao

    Background Paradoxical psoriasis (PP) is a class of adverse events associated with tumor necrosis factor α inhibitor (TNFi) that are realistically observed in the real world. We aim to quantify the signals of PP with TNFis in pediatric patients based on a pharmacovigilance study. Methods Data on pediatric PP cases linked to five TNFi drugs—etanercept, infliximab, adalimumab, certolizumab, and golimumab—were extracted from the FDA Adverse Event Reporting System (FAERS) database (Q1 2004 to Q1 2023). PP event reports were assessed using ROR, PRR, BCPNN, MGPS, and logistic regression to conduct a disproportionality analysis and identify signal disparities. Results The FAERS database noted 563 pediatric PP cases, with 33.69% male and 66.31% female, representing 0.58% of all pediatric TNFi adverse event reports. The average age was 14 years. Among the five TNFis, four showed disproportionate reporting of PP: etanercept [ROR = 18.53], infliximab [ROR = 17.19], adalimumab [ROR = 10.23], and certolizumab [ROR = 3.95]. Conclusions The real-world FAERS pharmacovigilance data showed the safety signal for PP associated with TNFi in pediatric patients. Etanercept, infliximab, adalimumab, and certolizumab showed disproportionate reporting. Impact This study collected and analysed the data of paradoxical psoriasis (PP) associated with TNFis in pediatric patients from a worldwide pharmacovigilance database. Reports of PP adverse events accounted for 0.58% of the overall TNFi adverse event reports in pediatric patients. Among the five TNFis, we found disproportionate reporting of PP with etanercept, infliximab, adalimumab, and certolizumab in pediatric patients.